TY - CHAP
T1 - Emerging molecular therapies for the treatment of acute lymphoblastic leukemia
AU - Vasekar, Monali
AU - Allen, Joshua E.
AU - Joudeh, Jamal
AU - Claxton, David
N1 - Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2013
Y1 - 2013
N2 - The improved molecular understanding of cancer initiation, progression, and therapeutic resistance has yielded several novel molecular events that are being targeted by emerging therapies. While the treatment of ALL is a success story in the pediatric population, achieving a sustained remission in the adult population remains an area of investigation. Nevertheless, certain therapies have significantly improved the overall survival for adult ALL patients that should continue to improve with the discovery of better molecular targets and targeted agents. Here, we discuss novel therapeutic options under clinical investigation for the treatment of Philadephia chromosome negative ALL including immunotherapy, monoclonal antibodies, and small molecules that may be used as single agent or adjuvant therapy in the management of adult ALL.
AB - The improved molecular understanding of cancer initiation, progression, and therapeutic resistance has yielded several novel molecular events that are being targeted by emerging therapies. While the treatment of ALL is a success story in the pediatric population, achieving a sustained remission in the adult population remains an area of investigation. Nevertheless, certain therapies have significantly improved the overall survival for adult ALL patients that should continue to improve with the discovery of better molecular targets and targeted agents. Here, we discuss novel therapeutic options under clinical investigation for the treatment of Philadephia chromosome negative ALL including immunotherapy, monoclonal antibodies, and small molecules that may be used as single agent or adjuvant therapy in the management of adult ALL.
UR - https://www.scopus.com/pages/publications/84873583634
UR - https://www.scopus.com/pages/publications/84873583634#tab=citedBy
U2 - 10.1007/978-1-4614-6176-0_16
DO - 10.1007/978-1-4614-6176-0_16
M3 - Chapter
C2 - 23288648
AN - SCOPUS:84873583634
SN - 9781461461753
T3 - Advances in Experimental Medicine and Biology
SP - 341
EP - 358
BT - Impact of Genetic Targets on Cancer Therapy
PB - Springer Science and Business Media, LLC
ER -